Difference between revisions of "Immunohistochemical staining"
m (→Vimentin & cytokeratin: fix ref.) |
(→Liver: wikify) |
||
Line 93: | Line 93: | ||
*HepPar-1 (hepatocytes paraffin antibody 1) - labels hepatocellular mitochondria.<ref name=pmid12502967>The diagnostic value of hepatocyte paraffin antibody 1 in differentiating hepatocellular neoplasms from nonhepatic tumors: a review. Lamps LW, Folpe AL. Adv Anat Pathol. 2003 Jan;10(1):39-43. Review. PMID 12502967.</ref> | *HepPar-1 (hepatocytes paraffin antibody 1) - labels hepatocellular mitochondria.<ref name=pmid12502967>The diagnostic value of hepatocyte paraffin antibody 1 in differentiating hepatocellular neoplasms from nonhepatic tumors: a review. Lamps LW, Folpe AL. Adv Anat Pathol. 2003 Jan;10(1):39-43. Review. PMID 12502967.</ref> | ||
HCC vs. cholangiocarcinoma: | [[HCC]] vs. [[cholangiocarcinoma]]: | ||
*TTF-1: ~90-100% +ve (cytoplasmic) in HCC vs. ~10% in choleangiocarcinoma.<ref name=pmid16627262>{{cite journal |author=Lei JY, Bourne PA, diSant'Agnese PA, Huang J |title=Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver |journal=Am. J. Clin. Pathol. |volume=125 |issue=4 |pages=519–25 |year=2006 |month=April |pmid=16627262 |doi=10.1309/59TN-EFAL-UL5W-J94M |url=}}</ref> | *TTF-1: ~90-100% +ve (cytoplasmic) in HCC vs. ~10% in choleangiocarcinoma.<ref name=pmid16627262>{{cite journal |author=Lei JY, Bourne PA, diSant'Agnese PA, Huang J |title=Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver |journal=Am. J. Clin. Pathol. |volume=125 |issue=4 |pages=519–25 |year=2006 |month=April |pmid=16627262 |doi=10.1309/59TN-EFAL-UL5W-J94M |url=}}</ref> | ||
Revision as of 03:55, 5 May 2011
Immunohistochemical staining, also immunostaining, is a powerful tool. It can help when ya can't quite figure it out from the histology or with conventional stains. Like all powerful stuff... it can also be trouble!
General (malignant) differential diagnosis
Malignancy | |||||||||||||||||||||||||||||||||||||||||||||||
Epithelial (Carcinoma) | Mesenchymal (Sarcoma) | Germ cell tumour | Neuroendocrine carcinoma | Lymphoid (Lymphoma) | Malignant melanoma | ||||||||||||||||||||||||||||||||||||||||||
- Carcinoma.
- AE1/AE3 - pankeratin.
- Others: EMA, HMWK, LMWK.
- Sarcoma.
- Vimentin.
- Many pathologists think this stain is totally useless.
- Vimentin.
- Germ cell tumours.
- PLAP (placental-like alkaline phosphatase) - not very sensitive.[1]
- Others: D2-40, OCT 3/4.
- Neuroendocrine carcinoma.
- Chromogranin A.
- Synaptophysin.
- CD56.
- Melanoma.
- Lymphoma/leukemia.
- CD45 (common leukocyte antigen).
- Others: CD30.
Keratins
Classification:[4]
- Low molecular weight keratins (LMWK): 7, 8/18, 19, 20.
- High molecular weight keratins (HWMK): 4, 10, 13, 14, 17.
Uses:
- CK8 (CAM5.2)[5] - used to look for mets from breast cancer in axillary lymph nodes.
- HWMK (e.g. K903[6]) - squamous cell carcinoma.
Organ specific
Thyroid and lung
- TTF-1 (thyroid transcription factor-1) -- +ve in thyroid gland malignancies.
Image: Adenocarcinoma with nuclear TTF-1 positivity (WC).
Breast markers
- GCDFP-15 (AKA BRST-2) -- specific, but NOT sensitive.
- ER (estrogen receptor) - in normal breast.
- PR (progesterone receptor) - in normal breast.
- HER2/neu - pathological, assoc. with worse prognosis.
- HER2/neu+ cancers Tx'ed with trastuzumab (Herceptin).
Prostate gland
- PSA - prostatic specific antigen.
- PSAP - prostatic specific acid phosphatase.
- p63 - stains nuclei of basal cell in normal prostate.
- 34betaE12 - stains basals cells in normal prostate.
- AMACR (racemase, P504S[8]) - present in adenocarcinoma (NOT in normal prostate).
- CAP cocktail - AKA CAP (AMACR, p63 and 34βE12).
Colorectal carcinoma markers
- CEA.
Small bowel
- CDX2.
- Villin.
Kidney
- RCC, EMA, CD10.
- CK7 -ve in clear cell RCC.
- AMACR +ve in papillary RCC.
- D2-40 +ve in ChRCC.
Xanthogranulomatous pyelonephritis:
- CD68 (for macrophages).
Ovary
- CA125, CK7+, CK20-.
- WT1 -- 90% in serous +ve.
Serous markers
- WT-1, CA-125, D2-40.
Liver
- AFP (alpha-fetaprotein).
- Glypican-3.
- Hepatocellular carcinoma (HCC) stains with glypican 3, while liver with dysplastic changes and/or cirrhotic changes does not.[9]
- HepPar-1 (hepatocytes paraffin antibody 1) - labels hepatocellular mitochondria.[10]
HCC vs. cholangiocarcinoma:
- TTF-1: ~90-100% +ve (cytoplasmic) in HCC vs. ~10% in choleangiocarcinoma.[11]
Mesothelium
- Calretinin.
- WT-1.
- D2-40.
- CK5/6.
Typically negative:
- CEA.
- TTF-1.
Pancreas
- CK17 - approx. 50% of pancreaticobiliary adenocarcinomas & patchy.[12]
- CK19.[13]
Neuropathology
General:
- S-100.
Glial:
- GFAP.
Neuronal:
- Synaptophysin.
- Chromogranin.
Specific entities:
- EMA +ve: meningioma, ependymomas (cytoplasm dot-like).[14]
Tumour (low-grade gliomas):
- IDH-1 +ve.
- Usually negative in Glioblastoma.
Miscellaneous
Macrophages
- CD68.
Special:
- S100 -- +ve in Rosai-Dorfman disease.
- CD1a -- +ve in Langerhans cell histiocytosis, Langerhans histocytes.
Special, less common:
One organ vs. another
Cervix vs. uterus
- Cervix (typically): CEA +ve,[20] p16 +ve.
- ... and ER -ve, PR -ve, vimentin -ve.
- Uterus (typically): vimentin +ve, ER +ve, PR +ve.[21]
- ... and CEA -ve, p16 -ve.
Additional Ref.:[22]
Liver vs. bile duct
Intrahepatic cholangiocarcinoma (ICC) vs. hepatocellular carcinoma (HCC):[23]
- ICC: CK19 (92.5%), MUC-1 (73.8%) +ve.
- HCC: HepPar-1 (85.6%), CD34 (87.8%) +ve.
Lymphomas
This is covered more extensively in the lymphoma article.
Lymphocytes
- CD45 (AKA common leukocyte antigen).
B-cells
- CD20.
- CD19 (flow only).
- PAX5.
- CD79a.
T-cells
- CD3 - general T-cell marker (marks both CD4 +ve and CD8 +ve cells).
- CD4.
- CD8.
- CD7.
- CD43.
Specific entities
Follicular lymphoma
- CD10 +ve, BCL6 +ve.
CLL
- CD5 +ve, CD23 +ve.
Mantle cell lymphoma
Hodgkin's lymphoma
This is covered more extensively in the Hodgkin lymphoma article.
Classic types:
- CD30 Reed-Sternberg cells (RSCs) +ve ~98%.[25]
- CD15 Reed-Sternberg cells +ve ~80%, stains neutrophils.
Germ cell tumours
Seminoma
- D2-40 +ve.[1]
- OCT 3/4 +ve.
Embryonal carcinoma
- CD30 +ve - cytoplasm, cell membrane, Golgi.
- Rarely positive in seminoma.
- CK7 +ve.[26]
- AE1/AE3 +ve.
Yolk sac tumour (endodermal sinus tumour)
- AFP (alpha fetoprotein).
Choriocarcinoma
- beta-hCG.
Bare bones mnemonic for GCTs
The germ cell tumour (GCT) IHC mnemonic ABCD:
- AFP = yolk sac tumour.
- Beta-hCG = choriocarcinoma.
- CD30 = embryonal carcinoma.
- D2-40 = seminoma.
Spindle cell lesions (usu. sarcoma)
MFH panel (MSH):
- CD34 - GIST, angiosarcoma, Kaposi sarcoma, solitary fibrous tumour/hemangiopericytoma, dermatofibrosarcoma protuberans (DFSP).
- S-100 - neural differentiation, melanoma.
- Desmin - smooth muscle.
- MIB1 - proliferation marker (target is Ki-67 protein).
- CD99 - blue small cell tumours, membranous staining EWS.
- BCL2 - synovial sarcoma, small cell lymphomas, spindle cell lipoma.[27][28]
- PGP 9.5.
- SMMS - smooth muscle.
- Caldesmon - muscle.
- PDGFR - GIST.
Muscle markers
- Desmin - all three types.
- Caldesmon - smooth muscle.
- Smooth muscle myosin - smooth muscle.
- MyoD1 - skeletal muscle.
Proliferation markers
- MIB1 - an antibody against the protein Ki-67 (a protein expressed in proliferating cells).
Note: MIB1 should not be confused with mindbomb homolog 1 (MIB-1), a gene that regulates apoptosis.[29]
Carcinomas
CK7 and CK20
CK7+ CK20-
- Ovary (but not mucinous).
- Breast.
- Endometrial.
- Lung (adenocarcinoma).
- Mesothelium.
- Salivary gland.
- Thyroid gland (all).
Mnemonic: OBE + lung x2 + H&N x2
CK7- CK20+
- Colorectal adenocarcinoma.
- Merkel cell tumour.
CK7+ CK20+
- Pancreatic adenocarcinoma.
- Ovary, mucinous subtype.
- Occasionally gastric adenocarcinoma, cholangiocarcinoma.
- Transitional cell carcinoma or urothelial cell carcinoma (UCC).
- Esophagus (adenocarcinoma).
Mnemonic: POOTE.
CK7- CK20-
- Neuroendocrine lung (small cell carcinoma).
- Adrenocortical carcinoma (ACC).
- Squamous cell carcinoma (all sites of the body).
- Hepatocellular carcinoma (HCC).
- Thymoma.
- Urogenital tumours - germ cell tumours.
- Renal cell carcinoma (clear cell type).
- Prostate adenocarcinoma.
Mnemonic: NASH TURP.
Vimentin & cytokeratin
A few tumours are positive for both vimentin and cytokeratins.
Common tumours:
Common tumours that uncommonly have the pattern:
Rare tumours:
References
- ↑ 1.0 1.1 Iczkowski KA, Butler SL, Shanks JH, et al (February 2008). "Trials of new germ cell immunohistochemical stains in 93 extragonadal and metastatic germ cell tumors". Hum. Pathol. 39 (2): 275-81. doi:10.1016/j.humpath.2007.07.002. PMID 18045648.
- ↑ Jani P, Chetty R, Ghazarian DM (April 2008). "An unusual composite pilomatrix carcinoma with intralesional melanocytes: differential diagnosis, immunohistochemical evaluation, and review of the literature". Am J Dermatopathol 30 (2): 174–7. doi:10.1097/DAD.0b013e318165b8fe. PMID 18360125.
- ↑ URL: http://www.ncbi.nlm.nih.gov/omim/156845. Accessed on: 18 August 2010.
- ↑ http://www.nordiqc.org/Epitopes/Cytokeratins/cytokeratins.htm
- ↑ Murata T, Nakashima Y, Takeuchi M, Sueishi K, Inomata H (September 1993). "The diagnostic use of low molecular weight keratin expression in sebaceous carcinoma". Pathol. Res. Pract. 189 (8): 888–93. PMID 7508102.
- ↑ URL: http://www.aruplab.com/guides/ug/tests/2003978.jsp. Accessed on: 17 March 2011.
- ↑ Jagirdar J (March 2008). "Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung". Arch. Pathol. Lab. Med. 132 (3): 384–96. PMID 18318581. http://journals.allenpress.com/jrnlserv/?request=get-abstract&issn=0003-9985&volume=132&page=384.
- ↑ http://www.antibodies-online.com/antibody/125649/P504S+alphaMethylacylCoA+Racemace+AMACR+Human/
- ↑ Anatelli F, Chuang ST, Yang XJ, Wang HL. (2008). "Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy". Am J Clin Pathol. 130 (2): 219-23?. doi:10.1309/WMB5PX57Y4P8QCTY. PMID 18628090.
- ↑ The diagnostic value of hepatocyte paraffin antibody 1 in differentiating hepatocellular neoplasms from nonhepatic tumors: a review. Lamps LW, Folpe AL. Adv Anat Pathol. 2003 Jan;10(1):39-43. Review. PMID 12502967.
- ↑ Lei JY, Bourne PA, diSant'Agnese PA, Huang J (April 2006). "Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver". Am. J. Clin. Pathol. 125 (4): 519–25. doi:10.1309/59TN-EFAL-UL5W-J94M. PMID 16627262.
- ↑ Goldstein NS, Bassi D (May 2001). "Cytokeratins 7, 17, and 20 reactivity in pancreatic and ampulla of vater adenocarcinomas. Percentage of positivity and distribution is affected by the cut-point threshold". Am. J. Clin. Pathol. 115 (5): 695–702. doi:10.1309/1NCM-46QX-3B5T-7XHR. PMID 11345833.
- ↑ Geller SA, Dhall D, Alsabeh R (March 2008). "Application of immunohistochemistry to liver and gastrointestinal neoplasms: liver, stomach, colon, and pancreas". Arch. Pathol. Lab. Med. 132 (3): 490–9. PMID 18318589.
- ↑ Perry, Arie; Brat, Daniel J. (2010). Practical Surgical Neuropathology: A Diagnostic Approach: A Volume in the Pattern Recognition series (1st ed.). Churchill Livingstone. pp. 12. ISBN 978-0443069826.
- ↑ Pernick NL, DaSilva M, Gangi MD, Crissman J, Adsay V (November 1999). ""Histiocytic markers" in melanoma". Mod. Pathol. 12 (11): 1072–7. PMID 10574605.
- ↑ URL: http://www.ncbi.nlm.nih.gov/omim/605545. Accessed on: 3 February 2011.
- ↑ URL: http://www.abcam.com/Macrophage-antibody-MAC387-FITC-ab7429.html. Accessed on: 3 February 2011.
- ↑ URL: http://www.abcam.com/Macrophage-antibody-MAC387-ab49408.html. Accessed on: 3 February 2011.
- ↑ URL: http://www.ncbi.nlm.nih.gov/omim/604862. Accessed on: 2 February 2011.
- ↑ 20.0 20.1 Alkushi A, Irving J, Hsu F, et al. (March 2003). "Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray". Virchows Arch. 442 (3): 271-7. doi:10.1007/s00428-002-0752-4. PMID 12647218.
- ↑ URL: http://www.nature.com/modpathol/journal/v19/n8/full/3800620a.html
- ↑ LAE 15 Jan 2009.
- ↑ [Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma] Dong H, Cong WL, Zhu ZZ, Wang B, Xian ZH, Yu H. Zhonghua Zhong Liu Za Zhi. 2008 Sep;30(9):702-5. Chinese. PMID 19173916.
- ↑ URL: http://atlasgeneticsoncology.org/Genes/BCL1.html. Accessed on: 17 December 2010.
- ↑ Humphrey, Peter A; Dehner, Louis P; Pfeifer, John D (2008). The Washington Manual of Surgical Pathology (1st ed.). Lippincott Williams & Wilkins. pp. 567. ISBN 978-0781765275.
- ↑ Cheville JC, Rao S, Iczkowski KA, Lohse CM, Pankratz VS (April 2000). "Cytokeratin expression in seminoma of the human testis". Am. J. Clin. Pathol. 113 (4): 583–8. doi:10.1309/3QLC-5MF1-JYXU-A5XX. PMID 10761461.
- ↑ Tadrous, Paul.J. Diagnostic Criteria Handbook in Histopathology: A Surgical Pathology Vade Mecum (1st ed.). Wiley. pp. 107. ISBN 978-0470519035.
- ↑ URL: http://ajp.amjpathol.org/cgi/content/full/160/3/759. Accessed on: 3 August 2010.
- ↑ http://www.genenames.org/data/hgnc_data.php?hgnc_id=21086
- ↑ URL: http://cat.inist.fr/?aModele=afficheN&cpsidt=2504165. Accessed on: 26 April 2011.
- ↑ Llombart-Bosch A, Lopez-Guerrero JA, Peydro-Olaya A (2002). "Synovial sarcoma (SS): new perspectives supported by modern technology". Arkh. Patol. 64 (3): 39–47. PMID 15338724.
- ↑ Itakura E, Tamiya S, Morita K, et al. (September 2001). "Subcellular distribution of cytokeratin and vimentin in malignant rhabdoid tumor: three-dimensional imaging with confocal laser scanning microscopy and double immunofluorescence". Mod. Pathol. 14 (9): 854–61. doi:10.1038/modpathol.3880401. PMID 11557780. http://www.nature.com/modpathol/journal/v14/n9/full/3880401a.html.
- ↑ Miettinen M, Fanburg-Smith JC, Virolainen M, Shmookler BM, Fetsch JF (August 1999). "Epithelioid sarcoma: an immunohistochemical analysis of 112 classical and variant cases and a discussion of the differential diagnosis". Hum. Pathol. 30 (8): 934–42. PMID 10452506.
External links
- Stanford Surgical Pathology IHC guide - standford.edu.